IP Library Granted Patent US 7,772,256
Granted Patent B2
US 7,772,256 · App. 12/042,795 · Granted Aug 10, 2010

2-heteroaryl substituted benzothiophenes and benzofuranes 709

Assignee: Astrazeneca AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,772,256
App. No.
12/042,795
Granted
Aug 10, 2010
Kind
B2
Abstract

The present invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.

Claims (14)

1. A compound or pharmaceutically acceptable salt thereof, wherein:

the compound is:

2-(2-fluoro-6-methylamino-pyridiny-3-yl)-benzofuran-5-ol, and

one or more of the atoms of the compound is optionally a detectable isotope.

2. A compound or salt thereof according to claim 1 , wherein one or more of the atoms of the compound is a detectable isotope.

3. A compound or salt thereof according to claim 1 , wherein:

one to six of the atoms of the compound is the detectable isotope 3 H,

one to three of the atoms of the compound is the detectable isotope 19 F, or

one of the atoms of the compound is a detectable isotope selected from 18 F and 11 C.

4. A compound or salt thereof according to claim 1 , wherein one of the atoms of the compound is the detectable isotope 11 C.

5. A compound or salt thereof according to claim 1 , wherein one of the atoms of the compound is the detectable isotope 18F.

6. A pharmaceutical composition for in vivo imaging of amyloid deposits, wherein the composition comprises:

a radio-labeled compound or salt thereof according to claims 1 , and

a pharmaceutically acceptable carrier.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 9, 2017
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: NAVIDEA BIOPHARMACEUTICALS, INC.
Reel/Frame 041518/0749 →
RELEASE OF SECURITY INTEREST Recorded Dec 24, 2015
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: NAVIDEA BIOPHARMACEUTICALS, INC.
Reel/Frame 037357/0256 →
SECURITY INTEREST Recorded May 15, 2015
From: NAVIDEA BIOPHARMACEUTICALS, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 035653/0441 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2008
From: ARZEL, ERWAN; SWAHN, BRITT-MARIE; WENSBO, DAVID
To: ASTRAZENECA AB
Reel/Frame 020620/0192 →
Continuity (2)
Provisional Application 6089314900 · Mar 6, 2007
Related Publication 20080221149A1 · Sep 11, 2008